Literature DB >> 26713284

Recombinant outer membrane protein F-B subunit of LT protein as a prophylactic measure against Pseudomonas aeruginosa burn infection in mice.

Hassan Heydari Farsani1, Iraj Rasooli1, Seyed Latif Mousavi Gargari1, Shahram Nazarian1, Shakiba Darwish Alipour Astaneh1.   

Abstract

AIM: To study immunogenicity of outer membrane protein F (OprF) fused with B subunit of LT (LTB), against Pseudomonas aeruginosa (P. aeruginosa).
METHODS: The OprF, a major surface exposed outer membrane protein that is antigenically conserved in various strains of P. aeruginosa, is a promising immunogen against P. aeruginosa. In the present study recombinant OprF and OprF-LTB fusion gene was cloned, expressed and purified. BALB/c mice and rabbits were immunized using recombinant OprF and OprF-LTB and challenged at the burn site with P. aeruginosa lethal dose of 10(4) CFU. The protective efficacy of rabbit anti OprF IgG against P. aeruginosa burn infection was investigated by passive immunization.
RESULTS: It has been well established that the LTB is a powerful immunomodulator with strong adjuvant activity. LTB as a bacterial adjuvant enhanced immunogenicity of OprF and anti OprF IgG titer in serum was increased. Experimental findings showed significantly higher average survival rate in burned mice immunized with OprF-LTB than immunized with OprF or the control group. Rabbits anti OprF IgG brought about 75% survival of mice following challenge with P. aeruginosa. Post challenge hepatic and splenic tissues of mice group immunized with OprF-LTB had significantly lower bacterial load than those immunized with OprF or the control groups.
CONCLUSION: These results demonstrate that LTB-fused OprF might be a potential candidate protein for a prophylactic measure against P. aeruginosa in burn infection.

Entities:  

Keywords:  B subunit of LT; Burn; Immunization; Outer membrane protein F; Pseudomonas aeruginosa

Year:  2015        PMID: 26713284      PMCID: PMC4686421          DOI: 10.5662/wjm.v5.i4.230

Source DB:  PubMed          Journal:  World J Methodol        ISSN: 2222-0682


  35 in total

Review 1.  Mucosal adjuvants.

Authors:  L C Freytag; J D Clements
Journal:  Vaccine       Date:  2005-03-07       Impact factor: 3.641

2.  A PLGA-encapsulated chimeric protein protects against adherence and toxicity of enterotoxigenic Escherichia coli.

Authors:  Shahram Nazarian; Seyed Latif Mousavi Gargari; Iraj Rasooli; Sadegh Hasannia; Nazanin Pirooznia
Journal:  Microbiol Res       Date:  2013-07-30       Impact factor: 5.415

3.  Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.

Authors:  Zhanhai Li; Michael R Kosorok; Philip M Farrell; Anita Laxova; Susan E H West; Christopher G Green; Jannette Collins; Michael J Rock; Mark L Splaingard
Journal:  JAMA       Date:  2005-02-02       Impact factor: 56.272

4.  Clinical study to assess the immunogenicity and safety of a recombinant Pseudomonas aeruginosa OprF-OprI vaccine in burn patients.

Authors:  Erfan Mansouri; Sigrid Blome-Eberwein; Josef Gabelsberger; Günter Germann; Bernd Ulrich von Specht
Journal:  FEMS Immunol Med Microbiol       Date:  2003-07-15

5.  Changes of microbial flora and wound colonization in burned patients.

Authors:  Serpil Erol; Ulku Altoparlak; Mufide N Akcay; Fehmi Celebi; Mehmet Parlak
Journal:  Burns       Date:  2004-06       Impact factor: 2.744

6.  A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.

Authors:  Eric T Weimer; Haiping Lu; Nancy D Kock; Daniel J Wozniak; Steven B Mizel
Journal:  Infect Immun       Date:  2009-04-06       Impact factor: 3.441

7.  A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients.

Authors:  Gerd Döring; Christoph Meisner; Martin Stern
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-21       Impact factor: 11.205

8.  Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa.

Authors:  Eric T Weimer; Sean E Ervin; Daniel J Wozniak; Steven B Mizel
Journal:  Vaccine       Date:  2009-09-08       Impact factor: 3.641

9.  Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections.

Authors:  U Baumann; E Mansouri; B-U von Specht
Journal:  Vaccine       Date:  2004-02-17       Impact factor: 3.641

10.  Enhancement of immune responses by an attenuated Salmonella enterica serovar Typhimurium strain secreting an Escherichia coli heat-labile enterotoxin B subunit protein as an adjuvant for a live Salmonella vaccine candidate.

Authors:  Jin Hur; John Hwa Lee
Journal:  Clin Vaccine Immunol       Date:  2010-12-15
View more
  1 in total

1.  In-silico design, expression, and purification of novel chimeric Escherichia coli O157:H7 OmpA fused to LTB protein in Escherichia coli.

Authors:  Aytak Novinrooz; Taghi Zahraei Salehi; Roya Firouzi; Sina Arabshahi; Abdollah Derakhshandeh
Journal:  PLoS One       Date:  2017-03-15       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.